Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 4/20 | 0.81 |
| ▸ | ADAMTS5 | Q9UNA0 | 8/20 | 0.78 |
| ▸ | PIM1 | P11309 | 6/20 | 0.70 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.70 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | MMP3 | P08254 | 1/20 | 0.62 |
| ▸ | MMP13 | P45452 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1247917 | 1.00 | AKR1B1 (0.81) | AKR1B1ADAMTS5PIM1PIM2HPGD | |
| SCHEMBL1247918 | 1.00 | AKR1B1 (0.81) | AKR1B1ADAMTS5PIM1PIM2HPGD | |
| SCHEMBL12891780 | 0.90 | AKR1B1 (1.00) | AKR1B1ADAMTS5PIM1PIM2HPGD | |
| SCHEMBL1248971 | 0.90 | AKR1B1 (1.00) | AKR1B1ADAMTS5PIM1PIM2HPGD | |
| SCHEMBL1248969 | 0.90 | AKR1B1 (1.00) | AKR1B1ADAMTS5PIM1PIM2HPGD | |
| SCHEMBL8186724 | 0.88 | ADAMTS5 (0.75) | AKR1B1ADAMTS5PIM1PIM2HPGD | |
| SCHEMBL8186722 | 0.88 | ADAMTS5 (0.75) | AKR1B1ADAMTS5PIM1PIM2HPGD | |
| SCHEMBL5248357 | 0.87 | ADAMTS5 (1.00) | AKR1B1ADAMTS5PIM1PIM2HPGD | |
| SCHEMBL5248348 | 0.87 | ADAMTS5 (1.00) | AKR1B1ADAMTS5PIM1PIM2HPGD | |
| SCHEMBL5509720 | 0.84 | ADAMTS5 (0.88) | AKR1B1ADAMTS5PIM1PIM2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | AKR1B1 3767/4885ADAMTS5 3693/4885PIM1 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.